ReviewNeurotoxicity research2013
Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease.
Review in Neurotoxicity research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 58 citations in OpenAlex.
- Monocolonization withMicrobiology spectrum · 2026Article
- Mindfulness-based stress reduction combined with reminiscence therapy: a non-pharmacological approach for older adults with mild cognitive impairment or mild dementia due to Alzheimer's disease.Frontiers in aging neuroscience · 2026Article
- Caveolin-1-Mediated Blood-Brain Barrier Disruption via MMP2/9 Contributes to Postoperative Cognitive Dysfunction.Neurochemical research · 2025Article
- Vulnerability of the Hippocampus to Insults: Links to Blood-Brain Barrier Dysfunction.International journal of molecular sciences · 2024Review
- Increased oxidative stress contributes to enhance brain amyloidogenesis and blunts energy metabolism in sucrose-fed rat: effect of AMPK activation.Scientific reports · 2021Article
- Diet, psychosocial stress, and Alzheimer's disease-related neuroanatomy in female nonhuman primates.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021Article
- Role of Nitric Oxide in Neurodegeneration: Function, Regulation, and Inhibition.Current neuropharmacology · 2021Review
- Sleep Disturbances in MCI and AD: Neuroinflammation as a Possible Mediating Pathway.Frontiers in aging neuroscience · 2020Review
- Sex Differences in Cardiovascular Disease and Cognitive Impairment: Another Health Disparity for Women?Journal of the American Heart Association · 2019Review
- Neuroprotective Strategies for Neurological Disorders by Natural Products: An update.Current neuropharmacology · 2019Review
- The effect of polypharmacy on prefrontal cortex activation during single and dual task walking in community dwelling older adults.Pharmacological research · 2019Article
- The effects of tramadol administration on hippocampal cell apoptosis, learning and memory in adult rats and neuroprotective effects of crocin.Metabolic brain disease · 2018Article
- URMC-099 facilitates amyloid-β clearance in a murine model of Alzheimer's disease.Journal of neuroinflammation · 2018Article
- Association between low thyroid-stimulating hormone, posterior cortical atrophy and nitro-oxidative stress in elderly patients with cognitive dysfunction.Archives of medical science : AMS · 2017Article
- Neuroprotective and Cognitive Enhancement Potentials of Angelica gigas Nakai Root: A Review.Scientia pharmaceutica · 2017Review
- Neuroprotective and cognitive-enhancing effects of the combined extract of Cyperus rotundus and Zingiber officinale.BMC complementary and alternative medicine · 2017Article
- Article
- Review
- Low-level laser therapy for beta amyloid toxicity in rat hippocampus.Neurobiology of aging · 2017Article
- Dysfunctional Sensory Modalities, Locus Coeruleus, and Basal Forebrain: Early Determinants that Promote Neuropathogenesis of Cognitive and Memory Decline and Alzheimer's Disease.Neurotoxicity research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Late onset Alzheimer's disease (AD) is the most common cause of progressive cognitive dysfunction and dementia. Despite considerable progress in elucidating the molecular pathology of this disease, we are not yet close to unraveling its etiopathogenesis. The hippocampus is at the epicenter of cognition being associated with learning and memory. A battery of neurotoxic modifiers has been delineated that may unleash deleterious heterogeneous pathologic impacts. Synergistically they target hippocampus causing its neuronal degeneration, gray matter volume atrophy, and progressive cognitive decline. The neurotoxic factors include aging, stress, depression, hypoxia/hypoxemia, hypertension, diabetes, obesity, alcohol abuse, smoking, malnutrition, and polypharmacy-to name a few. Addressing "upstream pathologies" due to these multiple and heterogeneous neurotoxic modifiers vis-a-vis hippocampal dysfunction is of paramount importance. The downstream-generated inflammatory cytokines, mitochondrial dysfunction, oxidative stress, hypoperfusion, excitotoxicity, amyloid beta, and neurofibrillary tangles may then trigger and sustain neurocognitive pathology. The failure of clinical trials in AD is due in part to this complex multifactorial neurotoxic-pathophysiological labyrinth. The key is to employ appropriate preventive and treatment strategies prior to significant hippocampus damage and its dysfunction. Prevention/reversal of the diverse neurotoxic impacts, delineated here, should be an integral part of therapeutic armamentarium, in order to ameliorate hippocampus dysfunction and to enhance memory in aging, mild cognitive impairment, and AD. Throughout, the paper highlights both the challenges presented by the ever present neurotoxic onslaught, and the opportunities to overcome them. Hence, arresting AD pathogenesis is achievable through early intervention. A targeted approach may ameliorate neurocognitive pathology and attenuate memory deterioration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.